Seroprevalence of Cytomegalovirus Among Voluntary Blood Donors in Erbil Province, North Iraq.

  • Haween T. Nanakaly Medical Research Centre, Hawler Medical University, Erbil, Kurdistan Region, Iraq
  • Bashdar Mahmud Hussen College of Dentistry, Hawler Medical University, Erbil, Kurdistan Region, Iraq
Keywords: Cytogemalovirus, blood donors, ELISA.


Background and objectives: Cytomegalovirus (CMV) is one of the most significant agent of infection in immunocompromised patients and transplant recipients. CMV is transmissible through transfusions of blood components. The present study amied to determine the seroprevalence of Cytomegalovirus (CMV) among voluntary blood donors in Erbil province, North of Iraq.

Methods: A prospective study was done on serum samples from 472 HIV, HCV, and HbsAg- seronegative healthy male voluntary blood donors were screened for CMV IgM /IgG using Enzyme-Linked Immunosorbent assay (ELISA).

Results: A total of 472 healthy voluntary blood donors were recruited; 148(31.36%) of the donors were anti-CMV IgG positive. There were no statistically significant differences between CMV seropositivity and age. Further, seven (1.48%) subjects were both anti-CMV IgM and IgG positive.

Conclusions: The  moderate seroprevalence of CMV IgG antibodies in the our donor population, underscores the importance of using strategies such as leukoreduction and transfusion with CMV-seronegative blood is recommended  for preventing and reducing  transmission of  CMV with the infected blood or blood products  in immunocompromised patients.


Akinbami, A.A., Akanmu, A.S., Adeyemo, T.A., Wright K.O., Dada, M.O., Dosunmu, A.O. (2009). Cytomegalovirus antibodies among healthy blood donors at Lagos University Teaching Hospital. SAMJ, 99(7):528-30.
Al-Sabri AMA, et al. (2017). Seroprevalence of Cytomega- lovirus among Healthy Blood Donors in Yemen. HSOA J Infect Non Infect Dis. 3: 016.
Arora, et al. (2018). Cytomegalovirus in Immunocompromised Patients. Contemporary Medical Research J. (11) ICV: 77.83
Badani, K.G. (2001). The immunocompromised patient and transfusion. Postgrad Med J, 77: 230–4.
Boeke, C.E., Pauly, M.E., Hatch-Stock, H., Jackson, J.B. (2008). CMV antibody prevalence and seroincidence in plateletpheresis donors. J Clin Apher, 23 (2):63-5.
Choudhury, N., Naik, S., Sharma, R.K, Elhence, P., Ramesh, V., Gupta, R.K. (1996). The prevalence of transfusion transmitted diseases in renal transplant recipients. Indian J PatholMicrobiol, 39:191-5.
Crough, T. and Khanna, R. (2009). Immunobiology of human cytomegalovirus: from bench to bedside. ClinMicrRev, 22(1):76-98.

Das, B., Kaur, G. Basu, S. (2014). Seroprevalence of Cytomegalovirus antibodies among blood donors and Mutitransfused recipients- A study from north India. Transfus Apher Sci, 50(3):438-42.
Diosi, P. and Kazanjian, P. (2003). Transmission or recurrence? A historical dilemma of iatrogenic infections due to cytomegalovirus.J Hist Med Allied Sci ,58 :56-78.
Dӧcke, W.D., Prosch, S., fietze, E., Reinke, P.S., Staffa, G.S., Hӧger, T.G. (1994). Cytomegalvirus reactivation and tumor necrosis factor. Lancet, 343:268-9.
Drew, W.L. (2004). Herpes Viruses. In : Ryan KJ, Ray CG, editors. Sherris Medical Microbiology. 4th ed. Columbus: McGraw Hill, 555-76.
Eisenfeld, L., Mclaughin, J.C, Mayo, D. (1992). Cytomegalovirus antibody detection in blood donors and mothers of very low birth weight neonates by using three serologic mthods. Diag. Microbial. Infect. Dis, 15: 125-8.
Emery, V.C. (2001). Investigation of CMV disease in immunocompromised patients. J Clin Pathol, 54:84-8.
Kraat, Y.J., Hendrix, R.M.G., Landini, M.P., Bruggeman, C.A. (1992). Comparison of four techniques for detecton of antibodies to cytomegalovirus. J. Clin.Microbiol., 30 (2): 522-4.
Kumar, H., Gupta, P.K., Kumar, S., Sarkar, R.S. (2008). Is seroprevalence of Anti Ig M CMV among blood donor relevant in India? Indian J Pathol Microbiol, 51: 351-2.
Ljungman, P., Griffiths, P., Paya, C. (2002). Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis, 34: 1094-7.
Ljungman, P. (2004). Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction. Br J Haematol, 125(2):107-16.
Mohammed K. and Abdul-Lateef M. (2014). Seroprevalence of cytomegalovirus among healthy students. Iraq. IOSR-JPBS, 9(1): 59-61.
Mussa, E.A., Elsayed, M.K., Hafez, A.M. (2005). Prevalence of Cytomegalovirus IgG antibody in blood donors. Egypt. J. Med. Lab. Sci., (ESIC), 14(1):41-8.
Mutlu, B., Gunlemez, A., Turker, G., Gokalp, A.S., Willke, A. (2008). Is serologic screening necessary in the donor bloods for cytomegalovirus seronegative blood transfusion to risky patients? Mikrobiyol Bul, 42(2):337-41.
Nichols, W.G., Price, T.H., Gooley, T., Corey, L., Boeckh, M. (2003) Transfusion transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood, 101(10):4195-200.
Ojide, C.k., Ophori, E.A., Eghafona, N.O, Omoti, C. (2012). Seroprevalence of Cytomegalovirus (CMV) amongst voluntary blood donors in University of Benin Teaching Hospital (UBTH), Edo State, Nigeria. BJMMR, 2(1):15-20.
Oladipo, E.K., Akinpelu, O.O., Oladipo, A.A., Edowhorhu, G. (2014). Seroprevalence of Cytomegalovirus (CMV) among Blood Donors at Bowen University Teaching Hospital Ogbomoso. Am J Med Biol Res, 2(3):72- 5.
Qu, L. and Tran, M.H. (2007). Cytomegalovirus (CMV) and transfusion medicine. Blood Bulletin, 9(1):1-2
Raghavan, M. and Marik, P.E. (2005). Anemia, Allogenic Blood Transfusion and Immunomodulation in the Critically Ill. Chest, 127:295-307.
Roback, J.D. (2002). CMV and blood transfusions.Rev Med Virol, 12:211-9.
Sia, I.G. and Pate,l R. (2000). New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients.ClinMicrobiol Rev, 13: 83–121.
Soderbeg, C., Fish, K., Nelson (1997). Reactivation of latent HCMV by allogenic stimulation of blood cells from healthy donors. Cell, 91(1):119-26.
Souza, M.A., Passos, A.M., Treitinger, A., Spada, C. (2010). Seroprevalence of cytomegalovirus antibodies in blood donors in southern, Brazil. Rev Soc Bras Med Trop,43(4):359-61.
SurgCdr, C.N., Chaudhari, Col, M.S. Bindra, (2009) .Seroprevalence of Cytomegalovirus among Voluntary Blood Donors . MJAFI, 65:252-4.
Taylor, G.H. (2003). Cytomegalovirus. Am Fam Phys, 67(3):519-24.
Thorat, S.B., Pawar G.L., Kulkarni, K.H., Khadilkar, S.V. (2004). Neurological manifestations in 102 patients admitted with immunosuppression due to HIV infection. Bombay Hos J, 46: 370-4.
Vamvakas, E.C. (2005). Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis.Transfus Med Rev, 19:181-99.
Ziaei, J.E., Movassagpour, A., Asgharzadeh, M., Dastgiri, S. (2013).
Seroprevalence of cytomegalovirus in blood donors in the northwest of Iran. J Analyt Res Clin Med, 1(2):96-100.
How to Cite
Nanakaly, H., and B. Hussen. “Seroprevalence of Cytomegalovirus Among Voluntary Blood Donors in Erbil Province, North Iraq.”. ZANCO Journal of Pure and Applied Sciences, Vol. 31, no. 3, June 2019, pp. 1-6, doi:10.21271/zjpas.31.3.1.
Biology and Medical Researches